Mehta R R, DasGupta T K
Breast Cancer Res Treat. 1987;9(1):61-7. doi: 10.1007/BF01806695.
Antiestrogen binding sites (AEBS) were measured in microsomal fractions of 102 malignant breast tumors and 24 nonmalignant breast tissues. The number of AEBS was determined by Scatchard analysis. The cytosol contents of estrogen and progesterone receptors were also analyzed in these tissues. Overall, 50% of the malignant tumors and 33% of the nonmalignant normal breast tissues had detectable contents of AEBS. No correlation was observed between cytosol estrogen receptor (ER) content and microsomal AEBS in the tumors. Detailed data analysis in patients at Stage IV disease revealed that 60% of estrogen receptor positive tumors had no detectable microsomal AEBS contents whereas in the remaining 40% tumors, high affinity AEBS were observed. On the other hand, AEBS were also detected in 35% of ER-poor tumors. Anti-estrogen binding sites were higher in tumors obtained from premenopausal women than in those of postmenopausal women. The incidence of AEBS-positive tumors or AEBS concentration was not influenced by either the patients' obesity or their disease stage.
在102例恶性乳腺肿瘤和24例非恶性乳腺组织的微粒体部分测量了抗雌激素结合位点(AEBS)。通过Scatchard分析确定AEBS的数量。还对这些组织中的雌激素和孕激素受体的胞浆含量进行了分析。总体而言,50%的恶性肿瘤和33%的非恶性正常乳腺组织有可检测到的AEBS含量。在肿瘤中,未观察到胞浆雌激素受体(ER)含量与微粒体AEBS之间的相关性。对IV期疾病患者的详细数据分析显示,60%的雌激素受体阳性肿瘤没有可检测到的微粒体AEBS含量,而在其余40%的肿瘤中,观察到高亲和力的AEBS。另一方面,在35%的雌激素受体含量低的肿瘤中也检测到了AEBS。绝经前妇女的肿瘤中抗雌激素结合位点高于绝经后妇女。AEBS阳性肿瘤的发生率或AEBS浓度不受患者肥胖或疾病分期的影响。